Clinical Trial Update: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly [Phase 3]

View source ↗

Summary

A Phase 3 trial compares pasireotide long-acting release (LAR) with octreotide LAR or lanreotide Autogel in patients with inadequately controlled acromegaly, re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• SIGNIFOR LAR (PASIREOTIDE)
• Sandostatin LAR (octreotide)
• Somatuline Autogel (lanreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2015-01-21